Oventus Successful ASX Listing & Market Update
Key Points:
• O2Vent TTM registered with TGA and sales launch commences
• 510k application lodged for O2Vent TTM with FDA
• US launch planed for last quarter 2016
• Manufacturing including 3D printing capability scaled up
• Successful listing on the ASX with fully subscribed IPO
• Oventus attracts strong interest at Denver (US) conferences
Brisbane, Australia XX July 2016: Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX: OVN) is pleased to provide an update on its activity as the company delivers on its plans to grow and disrupt the multi-billion dollar global sleep devices market.
Oventus has:
• Registered its next generation O2Vent TTM titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through and expanded network of dentists;
• Lodged a 510k application with the US Food and Drug Administration (FDA) for the O2Vent TTM;
• Scaled up its in-house 3D printing capability in preparation for a ramp up in production;
• Successfully listed on the Australian Securities Exchange (ASX) via a fully subscribed IPO underwritten by Bell Potter with strong support from Ord Minnett, Baillieu Holst and Peloton Capital;
• Exhibited at both the American Academy of Dental SLEEP and SLEEP Medicine conferences in Denver, Colorado, the world’s largest meetings of sleep experts where there was significant interest in Oventus’ products, pipeline and their innovative design. Interest came from dentists and sleep clinicians as well as strategic partners;
Oventus Successful ASX Listing & Market Update
Key Points:
• O2Vent TTM registered with TGA and sales launch commences
• 510k application lodged for O2Vent TTM with FDA
• US launch planed for last quarter 2016
• Manufacturing including 3D printing capability scaled up
• Successful listing on the ASX with fully subscribed IPO
• Oventus attracts strong interest at Denver (US) conferences
Brisbane, Australia XX July 2016: Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX: OVN) is pleased to provide an update on its activity as the company delivers on its plans to grow and disrupt the multi-billion dollar global sleep devices market.
Oventus has:
• Registered its next generation O2Vent TTM titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through and expanded network of dentists;
• Lodged a 510k application with the US Food and Drug Administration (FDA) for the O2Vent TTM;
• Scaled up its in-house 3D printing capability in preparation for a ramp up in production;
• Successfully listed on the Australian Securities Exchange (ASX) via a fully subscribed IPO underwritten by Bell Potter with strong support from Ord Minnett, Baillieu Holst and Peloton Capital;
• Exhibited at both the American Academy of Dental SLEEP and SLEEP Medicine conferences in Denver, Colorado, the world’s largest meetings of sleep experts where there was significant interest in Oventus’ products, pipeline and their innovative design. Interest came from dentists and sleep clinicians as well as strategic partners;
• Boosted the number of dentists distributing Oventus’ products with enrolments for training growing and geographic regions reached expanding;
• Advanced plans for growing into the US by identifying key sites to target and entering discussions.
“Oventus is a company with a unique oral mouthguard device that can help people globally who suffer from obstructive sleep apnoea and snoring,” said Chairman Dr Mel Bridges.
“I’m proud to be part of this company and our leadership team, who are all experienced in the commercialisation and global roll out of medical devices, as it starts out on a new phase of growth as an ASX listed company,” he added. The company’s O2VentTM range incorporates an airway to bypass nasal, soft palate and tongue obstructions. The device and its airway advances the treatment of sleep conditions and provides patients with a new option to current devices.
The company recently received clearance from the US Food and Drug Administration (FDA) for the O2VentTM Mono device, which will be used as a platform for clearance of the O2VentTM T device.
Oventus’ devices have been validated through a clinical trial and received strong positive feedback from users. The company continues to work on its pipeline of devices which will enable it to reach a wider number of patients suffering sleep disordered breathing issues.
The company’s intellectual property is closely protected with its platform patent issued in Australia and with multiple patent applications in key jurisdictions.
With the listing of Oventus on the ASX, the company anticipates receiving independent research coverage.
“I welcome new shareholders to Oventus and look forward to sharing with them future updates on our progress,” Dr Bridges said.
• O2Vent TTM registered with TGA and sales launch commences
• 510k application lodged for O2Vent TTM with FDA
• US launch planed for last quarter 2016
• Manufacturing including 3D printing capability scaled up
• Successful listing on the ASX with fully subscribed IPO
• Oventus attracts strong interest at Denver (US) conferences
Brisbane, Australia XX July 2016: Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX: OVN) is pleased to provide an update on its activity as the company delivers on its plans to grow and disrupt the multi-billion dollar global sleep devices market.
Oventus has:
• Registered its next generation O2Vent TTM titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through and expanded network of dentists;
• Lodged a 510k application with the US Food and Drug Administration (FDA) for the O2Vent TTM;
• Scaled up its in-house 3D printing capability in preparation for a ramp up in production;
• Successfully listed on the Australian Securities Exchange (ASX) via a fully subscribed IPO underwritten by Bell Potter with strong support from Ord Minnett, Baillieu Holst and Peloton Capital;
• Exhibited at both the American Academy of Dental SLEEP and SLEEP Medicine conferences in Denver, Colorado, the world’s largest meetings of sleep experts where there was significant interest in Oventus’ products, pipeline and their innovative design. Interest came from dentists and sleep clinicians as well as strategic partners;
Oventus Successful ASX Listing & Market Update
Key Points:
• O2Vent TTM registered with TGA and sales launch commences
• 510k application lodged for O2Vent TTM with FDA
• US launch planed for last quarter 2016
• Manufacturing including 3D printing capability scaled up
• Successful listing on the ASX with fully subscribed IPO
• Oventus attracts strong interest at Denver (US) conferences
Brisbane, Australia XX July 2016: Sleep disorder device manufacturer and developer Oventus Medical Ltd. (ASX: OVN) is pleased to provide an update on its activity as the company delivers on its plans to grow and disrupt the multi-billion dollar global sleep devices market.
Oventus has:
• Registered its next generation O2Vent TTM titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through and expanded network of dentists;
• Lodged a 510k application with the US Food and Drug Administration (FDA) for the O2Vent TTM;
• Scaled up its in-house 3D printing capability in preparation for a ramp up in production;
• Successfully listed on the Australian Securities Exchange (ASX) via a fully subscribed IPO underwritten by Bell Potter with strong support from Ord Minnett, Baillieu Holst and Peloton Capital;
• Exhibited at both the American Academy of Dental SLEEP and SLEEP Medicine conferences in Denver, Colorado, the world’s largest meetings of sleep experts where there was significant interest in Oventus’ products, pipeline and their innovative design. Interest came from dentists and sleep clinicians as well as strategic partners;
• Boosted the number of dentists distributing Oventus’ products with enrolments for training growing and geographic regions reached expanding;
• Advanced plans for growing into the US by identifying key sites to target and entering discussions.
“Oventus is a company with a unique oral mouthguard device that can help people globally who suffer from obstructive sleep apnoea and snoring,” said Chairman Dr Mel Bridges.
“I’m proud to be part of this company and our leadership team, who are all experienced in the commercialisation and global roll out of medical devices, as it starts out on a new phase of growth as an ASX listed company,” he added. The company’s O2VentTM range incorporates an airway to bypass nasal, soft palate and tongue obstructions. The device and its airway advances the treatment of sleep conditions and provides patients with a new option to current devices.
The company recently received clearance from the US Food and Drug Administration (FDA) for the O2VentTM Mono device, which will be used as a platform for clearance of the O2VentTM T device.
Oventus’ devices have been validated through a clinical trial and received strong positive feedback from users. The company continues to work on its pipeline of devices which will enable it to reach a wider number of patients suffering sleep disordered breathing issues.
The company’s intellectual property is closely protected with its platform patent issued in Australia and with multiple patent applications in key jurisdictions.
With the listing of Oventus on the ASX, the company anticipates receiving independent research coverage.
“I welcome new shareholders to Oventus and look forward to sharing with them future updates on our progress,” Dr Bridges said.